Fondaparinux Sodium Injection shortage
Fondaparinux Sodium Injection is currently listed in shortage by the FDA. The FDA lists 4 affected products. This page was last refreshed from FDA data on Sep 22, 2026.
Jiangsu Hengrui is discontinuing fondaparinux sodium injection, and the change may be permanent. The same medicine in all strengths is still listed by other manufacturers, including Sandoz, Dr. Reddy's Laboratories, and Eugia.
Don’t stop or change your therapy on your own — talk with your prescriber about the plan that fits you, and ask your pharmacist what’s actually available (see options).
Do you take this drug? See the ‘What to do’ recommendation from Dr. Brian Staiger, PharmD →What’s in shortage — at a glance
These figures count only the manufacturers that reported this shortage to the FDA — not every company that makes Fondaparinux Sodium Injection. Other makers that haven’t reported a problem are shown in the green card below.
Shortage timeline
-
Sep 29, 2025Currently in shortage4 of 4 products affected.
-
Sep 29, 2025First reported to the FDA4 products first listed.
Built from FDA posting and update dates. The end date FDA publishes is the posting/update date, not a true resolution date, so durations are approximate.
What exactly is on backorder — by manufacturer
Manufacturer: Jiangsu Hengrui Pharmaceuticals Co. (US Agent eVenus Pharmaceutical Laboratories, Inc.) 📞 609-395-8625 ext. 203 (US Agent eVenus Pharmaceutical Laboratories, Inc.) 4 NDCS click to expand
| Status | NDC / product | Strength | Availability | Related information | Reason |
|---|---|---|---|---|---|
| To Be Discontinued | Fondaparinux Sodium, Injection, 5 mg/.4 mL (NDC 0781-3454-95) | — | — | Discontinuation of the manufacture of the drug; Distributed by Sandoz Inc. | — |
| To Be Discontinued | Fondaparinux Sodium, Injection, 2.5 mg/.5 mL (NDC 0781-3443-95) | — | — | Discontinuation of the manufacture of the drug; Distributed by Sandoz Inc. | — |
| To Be Discontinued | Fondaparinux Sodium, Injection, 10 mg/.8 mL (NDC 0781-3476-95) | — | — | Discontinuation of the manufacture of the drug; Distributed by Sandoz Inc. | — |
| To Be Discontinued | Fondaparinux Sodium, Injection, 7.5 mg/.6 mL (NDC 0781-3465-95) | — | — | Discontinuation of the manufacture of the drug; Distributed by Sandoz Inc. | — |
These rows are manufacturer reports to the FDA for Fondaparinux Sodium Injection — they do not necessarily cover every manufacturer that makes this drug. A company appears here only if it told the FDA it has a supply problem, so other makers may still have stock. That’s the basis for the Where else can I get Fondaparinux Sodium Injection? options further down this page.
Why is Fondaparinux Sodium Injection in shortage?
Jiangsu Hengrui Pharmaceuticals (whose fondaparinux products were distributed in the U.S. by Sandoz Inc.) has made the decision to permanently stop manufacturing all of their fondaparinux sodium injection products. This affects every strength they made:
- 2.5 mg/0.5 mL
- 5 mg/0.4 mL
- 7.5 mg/0.6 mL
- 10 mg/0.8 mL
The FDA did not share a specific public reason for why this manufacturer chose to discontinue production. It's worth knowing that this report only covers Jiangsu Hengrui/Sandoz's products — it doesn't necessarily mean fondaparinux is gone from every supplier out there.
Based on the manufacturer-reported reason(s) and notes on file with the FDA for Fondaparinux Sodium Injection, summarized in plain English by HelloPharmacist. A drug can be short for more than one reason, and the FDA updates these as manufacturers report changes.
What should I do if I take Fondaparinux Sodium Injection?
Fondaparinux Sodium Injection is currently on the FDA drug-shortage list. I want to walk you through what this means so you know what to expect and what to do next.
This shortage report covers all four strengths: 2.5 mg/0.5 mL, 5 mg/0.4 mL, 7.5 mg/0.6 mL, and 10 mg/0.8 mL. Right now, none of these strengths has an available source from the manufacturer that filed this report. The reported reason is that this manufacturer (distributed by Sandoz Inc.) is discontinuing its production. Because this is listed as a discontinuation, the supply problem from this maker may be permanent — which makes a conversation with your prescriber the right next step.
Keep in mind this report reflects only the manufacturer who filed it. Other companies still make this same medicine, so it may still be available elsewhere.
Here is what I suggest:
- Do not stop, skip, or change your dose on your own — this medicine is important, and changes should be guided by a professional.
- Ask your pharmacy to check wholesalers and other makers. The same medicine (fondaparinux sodium) is also listed from Dr. Reddy's Laboratories and Eugia US LLC, though these may not be in your local pharmacy's stock.
- If your exact strength cannot be found, talk with your prescriber or pharmacist about options, such as a clinician-chosen alternative.
Manufacturer contact numbers are listed on this page for reference; your pharmacy usually handles those calls. This is general, national information and may not match your local pharmacy's actual supply.
- Don’t stop or change the medication on your own — talk to your prescriber first.
- If this is part of an ongoing or essential regimen (for example HIV treatment or prevention, seizure, heart, transplant, diabetes or mental-health medicines), do not skip or ration doses — contact your pharmacist or prescriber right away to arrange continued supply before you run out.
- Ask your pharmacy to check other manufacturers, strengths, package sizes, and nearby stores.
- Ask your prescriber whether a different strength, formulation, or the brand/generic version is appropriate.
Uses, dosing, side effects, prices, and the complete FDA label — written in plain English and pharmacist-reviewed.
Where else can I get Fondaparinux Sodium Injection?
FDA shortages are manufacturer-reported — a company only shows up on the shortage list if it told the FDA it has a supply problem, so not every maker of Fondaparinux Sodium Injection is necessarily short. Below we pull together the other still-marketed options that are not reported in shortage: the same medicine from manufacturers that haven’t reported a problem, and alternative dosage forms. These may still be out of stock at your pharmacy, and only your prescriber or pharmacist can decide what’s right for you.
Same medicine, other manufacturers (not reported short)
Same active ingredient, dosage form & route as the shortage (matched on the FDB HICL ingredient code), from makers that have not filed a shortage with the FDA:
| Product | Strength | Form / route | Manufacturer | NDC |
|---|---|---|---|---|
| Fondaparinux Sodium | FONDAPARINUX SODIUM 2.5 mg/.5mL | Injection · Subcutaneous | Sandoz Inc. | 00781-3443-12 |
| Fondaparinux Sodium | FONDAPARINUX SODIUM 5 mg/.4mL | Injection · Subcutaneous | Sandoz Inc. | 00781-3454-12 |
| Fondaparinux Sodium | FONDAPARINUX SODIUM 7.5 mg/.6mL | Injection · Subcutaneous | Sandoz Inc. | 00781-3465-12 |
| Fondaparinux Sodium | FONDAPARINUX SODIUM 10 mg/.8mL | Injection · Subcutaneous | Sandoz Inc. | 00781-3476-12 |
| Fondaparinux Sodium | FONDAPARINUX SODIUM 2.5 mg/.5mL | Injection · Subcutaneous | Dr. Reddy's Laboratories Limited | 55111-0678-02 |
| Fondaparinux Sodium | FONDAPARINUX SODIUM 5 mg/.4mL | Injection · Subcutaneous | Dr. Reddy's Laboratories Limited | 55111-0679-02 |
| Fondaparinux Sodium | FONDAPARINUX SODIUM 7.5 mg/.6mL | Injection · Subcutaneous | Dr. Reddy's Laboratories Limited | 55111-0680-02 |
| Fondaparinux Sodium | FONDAPARINUX SODIUM 10 mg/.8mL | Injection · Subcutaneous | Dr. Reddy's Laboratories Limited | 55111-0681-02 |
| Fondaparinux Sodium | FONDAPARINUX SODIUM 2.5 mg/.5mL | Injection, Solution · Subcutaneous | Eugia US LLC | 55150-0230-02 |
| Fondaparinux Sodium | FONDAPARINUX SODIUM 5 mg/.4mL | Injection, Solution · Subcutaneous | Eugia US LLC | 55150-0231-02 |
| Fondaparinux Sodium | FONDAPARINUX SODIUM 7.5 mg/.6mL | Injection, Solution · Subcutaneous | Eugia US LLC | 55150-0232-02 |
| Fondaparinux Sodium | FONDAPARINUX SODIUM 10 mg/.8mL | Injection, Solution · Subcutaneous | Eugia US LLC | 55150-0233-02 |
Therapeutic equivalents & pricing 21 productsclick to expand
Orange Book–rated equivalents of the affected strengths, with the latest NADAC price (a federal retail-acquisition benchmark, not your copay) and an evidence-based availability label. Cheapest first.
| Product | Manufacturer | Package | NADAC $/unit | AB rating | Availability |
|---|---|---|---|---|---|
| Fondaparinux Sodium 2.5 mg/.5mL | Dr. | 2 syringes | $12.256 | AP | Availability likely |
| Fondaparinux Sodium 10 mg/.8mL | Dr. | 2 syringes | $18.369 | AP | FDA listed |
| Fondaparinux Sodium 2.5 mg/.5mL | Sandoz | 10 syringes | $22.162 | — | Availability likely |
| Fondaparinux Sodium 2.5 mg/.5mL | Mylan | 10 syringes | $22.162 | AP | Availability likely |
| fondaparinux sodium 2.5 mg/.5mL | Zydus | 10 syringes | $22.162 | AP | Availability likely |
| Fondaparinux Sodium 10 mg/.8mL | Sandoz | 10 syringes | $46.033 | — | Availability likely |
| Fondaparinux Sodium 10 mg/.8mL | Mylan | 10 syringes | $46.033 | AP | Availability likely |
| fondaparinux sodium 10 mg/.8mL | Zydus | 10 syringes | $46.033 | AP | Availability likely |
| Fondaparinux Sodium 5 mg/.4mL | Sandoz | 10 syringes | $55.313 | — | Availability likely |
| Fondaparinux Sodium 5 mg/.4mL | Mylan | 10 syringes | $55.313 | AP | Availability likely |
| fondaparinux sodium 5 mg/.4mL | Zydus | 10 syringes | $55.313 | AP | Availability likely |
| fondaparinux sodium 5 mg/.4mL | Italfarmaco | 10 syringes | — | AP | FDA listed |
| Fondaparinux Sodium 5 mg/.4mL | Dr. | 2 syringes | — | AP | FDA listed |
| Fondaparinux Sodium 5 mg/.4mL | Eugia | 2 syringes | — | AP | FDA listed |
| Arixtra 5 mg/.4mL | Mylan | 10 syringes | — | AP | FDA listed |
| fondaparinux sodium 2.5 mg/.5mL | Italfarmaco | 10 syringes | — | AP | FDA listed |
| Fondaparinux Sodium 2.5 mg/.5mL | Eugia | 2 syringes | — | AP | FDA listed |
| Arixtra 2.5 mg/.5mL | Mylan | 10 syringes | — | AP | FDA listed |
| fondaparinux sodium 10 mg/.8mL | Italfarmaco | 10 syringes | — | AP | FDA listed |
| Fondaparinux Sodium 10 mg/.8mL | Eugia | 2 syringes | — | AP | FDA listed |
| Arixtra 10 mg/.8mL | Mylan | 10 syringes | — | AP | FDA listed |
Equivalents share the same ingredient, strength, dosage form and route; an AB rating means the FDA considers them substitutable. NADAC is a national retail-pharmacy acquisition benchmark from CMS — not what you pay. Availability is inferred from recent pricing, not a stock check.
Other drugs in the same treatment class
These are different medicines — not other versions of Fondaparinux Sodium Injection — that fall in the same broad treatment class (heparin and related preparations) . They are not automatic substitutes: they can differ in how they work, dosing, effectiveness, side effects and what they’re approved to treat. Do not switch on your own. This list is for information only — ask your prescriber or pharmacist whether any of them is appropriate for you.
Identity & classification
Where does this data come from?
Other hematology shortages
Fondaparinux Sodium Injection shortage FAQs
Is Fondaparinux Sodium Injection in shortage?
Which products are affected?
When will Fondaparinux Sodium Injection be available again?
Can I still get Fondaparinux Sodium somewhere?
What should I do if I take Fondaparinux Sodium Injection?
Still have a question about the Fondaparinux Sodium Injection shortage?
Ask a pharmacist about this shortage →View Fondaparinux Sodium Injection on the FDA drug-shortage database →
Where does this data come from?
/drug/shortages) — drug, manufacturer & contact, NDC/product, status, availability, reason, therapeutic category and posting/update dates. Current / To Be Discontinued = active; Resolved is kept for history. The Supply-Risk rating is assessed per active ingredient and adds the FDA NDC Directory (still-marketed manufacturers by ingredient & form); same-medicine and equivalent products use First Databank classification + CMS NADAC pricing; Medicaid use + most-affected states come from CMS Medicaid State Drug Utilization Data. Reference only — confirm current status with the manufacturer or FDA before acting on it.